通心络治疗急性脑梗塞疗效观察及作用分析  

Observation of the Result of Tongxinluo Capsule for the Treatment of Acute Cerebral Infarction and Analysis of Its Mechanism

作　　者：丁小君[1] 徐严明[1] 刘凌[1] 姜晓峰[1] 刘小丽[1] 罗祖明[1] 

机构地区：[1]四川大学华西医院神经内科,四川成都610041

出　　处：《华西医学》2003年第4期494-495,共2页West China Medical Journal

摘　　要：目的 :了解通心络治疗急性脑梗死的效果并对其作用机制作初步探讨。方法 :86例急性脑梗死患者随机分为通心络治疗试验组 (4 3)和对照组 (4 3) ,采用改良爱丁堡 -斯堪的纳维亚量表 (mESSS) ,日常生活活动量表 (BI)对急性脑梗死患者通心络治疗组和对照组分别进行从入院至病后 90天系列神经功能缺损评分及日常生活活动能力评分 ,并检测外周血IL - 1水平。结果 :通心络治疗组病后 14、 30、 6 0、 90d的神经功能缺损与对照组有显著性差异 (减少值 :mESSS ,4 2 4 ,8 32 ,10 6 8,13 0 2 ,VS 2 6 5 ,4 0 7,5 34,6 2 5 ) ;病后 6 0、 90d日常生活活动能力评分通心络治疗组病比对照组高 (BI:86 5 5 ,90 83,VS 71 5 8,75 12 ) ;病后 14d时通心络治疗组外周血IL - 1水平降低较对照组明显 (11 75ng/ml,VS 7 83ng/ml)。结论Objective:To observe the clinical result of Tongxinluo in treating acute cerebral infarction and analyzing its mechanism.Methods:Eighty-six patients suffered from acute cerebral infarction were divided randomly into Tongxinluo trial group and control group. Modified Edinberg-Scandinavian stroke scale(mESSS) was used to evaluate the neurological defects at admission,7th,14th day,1,2 and 3 months after stroke.Barth Index(BI) was used to evaluate the activity of daily living at 1,2 and 3 months after stroke.The plasma levels of IL-1 was measured at admission and 14 days after stroke. Results: Compared with those of the control group,the decrease of defect scores of neurological function on the day of 14,1,2 and 3 months after the onset of stroke were more significant(mESSS,4.24,8.32,10.68,and 13.02,VS 2.65,4.07,5.34 and 6.25 respectively,P<0.05);the scores of BI on 2 and 3 month were significantly increased(86.55 and 90.83 VS 71.58 and 75.12 respectively,P<0.05);The decrease of the plasma level of IL-1 had statistical significance compared with that of the control group(11.75 ng/ml VS 7.83 ng/ml).Conclusions Tongxinluo could reduce the defects neurological function and improve the prognosis in the patients having acute cerebral infarct.

关 键 词：通心络 治疗 急性脑梗塞 疗效观察 作用分析 日常生活活动量表 

分 类 号：R743.33[医药卫生—神经病学与精神病学] R972.3[医药卫生—临床医学]